Predictive in silico modeling for hERG channel blockers

Drug Discovery Today

Volumn 10, Issue 2, 2005, Pages 149-155

  Aronov, Alex M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ASTEMIZOLE; CISAPRIDE; CLOFILIUM; GREPAFLOXACIN; IBUTILIDE; NEUROLEPTIC AGENT; PIPERANOMETOZINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG BLOCKING AGENT; SERTINDOLE; TERFENADINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CARDIOTOXICITY; COMPUTER MODEL; DRUG ACTIVITY; GENE MUTATION; HEART DEATH; HUMAN; IC 50; LONG QT SYNDROME; NONHUMAN; PHARMACOPHORE; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; SUDDEN DEATH;

CATION TRANSPORT PROTEINS; DEATH, SUDDEN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13844254976     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03278-7     Document Type: Review

References (41)

1. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25
2. Ajay, et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J Med Chem. 41:1998;3314-3324
3. Egan W.J., et al. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discov. Devel. 5:2002;540-549
4. Teague S.J., et al. The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748
5. Oprea T.I., et al. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41:2001;1308-1315
6. Beresford A.P., et al. In silico prediction of ADME properties: are we making progress? Curr. Opin. Drug Discov. Devel. 7:2004;36-42
7. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today. 8:2003;927-933
8. Jalaie M., et al. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions. Methods Mol. Biol. 275:2004;449-520
9. Ekins S., Erickson J.A. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 30:2002;96-99
10. Penzotti J.E., et al. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem. 45:2002;1737-1740
11. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today. 9:2004;276-285
12. Brown A.M. Drugs, hERG and sudden death. Cell Calcium. 35:2004;543-547
13. Pearlstein R., et al. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J. Med. Chem. 46:2003;2017-2022
14. Towbin J.A., et al. Genotype and severity of long QT syndrome. Drug Metab. Dispos. 29:2001;574-579
15. Antzelevitch C., Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr. Opin. Cardiol. 17:2002;43-51
16. Mitcheson J.S., Perry M.D. Molecular determinants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. Devel. 6:2003;667-674
17. Redfern W.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:2003;32-45
18. Netzer R., et al. Screening lead compounds for QT interval prolongation. Drug Discov. Today. 6:2001;78-84
19. Wood C., et al. Patch clamping by numbers. Drug Discov. Today. 9:2004;434-441
20. Cavero I., et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1:2000;947-973
21. Friesen R.W., et al. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. J. Med. Chem. 46:2003;2413-2426
22. McCauley J.A., et al. NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem. 47:2004;2089-2096
23. Mitcheson J.S., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12329-12333
24. Pearlstein R.A., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13:2003;1829-1835
25. Doyle D.A., et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 280:1998;69-77
26. Jiang Y., et al. Crystal structure and mechanism of a calcium-gated potassium channel. Nature. 417:2002;515-522
27. Jiang Y., et al. X-ray structure of a voltage-dependent K+ channel. Nature. 423:2003;33-41
28. Blaustein R.O., Miller C. Ion channels: shake, rattle or roll? Nature. 427:2004;499-500
29. Cohen B.E., et al. Answers and questions from the KvAP structures. Neuron. 39:2003;395-400
30. Fernandez D., et al. Physicochemical features of the HERG channel drug binding site. J Biol Chem. 279:2004;10120-10127
31. Chen J., et al. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A. 99:2002;12461-12466
32. Ekins S., et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301:2002;427-434
33. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Trans. 31:2003;611-614
34. Cavalli A., et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 45:2002;3844-3853
35. Keseru G.M. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett. 13:2003;2773-2775
36. Roche O., et al. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem. 3:2002;455-459
37. Buyck C. An in silico model for detecting potential HERG blocking. Ford M.,, et al. EuroQSAR 2002. Designing drugs and crop protectants: processes, problems, and solutions. 2003;86-89 Blackwell Publishing
38. Tong W., et al. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J. Chem. Inf. Comput. Sci. 38:1998;669-677
39. Aronov A.M., Goldman B.B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem. 12:2004;2307-2315
40. Carhart R.E., et al. Atom pairs as molecular features in structure-activity studies: definition and application. J. Chem. Inf. Comput. Sci. 25:1985;64-73
41. Zolotoy A.B., et al. Physicochemical determinants for drug induced blockade of HERG Potassium Channels: Effect of Charge and Charge Shielding. Curr Med Chem - Cardiovasc Hematol Agents. 1:2003;225-241